Valproic acid alters differential protein expression in SH-SY5Y cells

Neural Regeneration Research

Volumn 6, Issue 27, 2011, Pages 2134-2139

  Dong, Zhong ^a   Wang, Ying ^a   Chang, Ming ^a   Li, Guoyi ^a   Hu, Linsen ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Matrix assisted laser desorption ionization; Neural regeneration; Proteomics; SH SY5Y cells; Two dimensional difference gel electrophoresis; Valproic acid

Indexed keywords

ATP6V1B2 PROTEIN; EUKARYOTIC TRANSLATION INITIATION FACTOR 4A ISOFORM 1; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; INITIATION FACTOR 4A; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PROTEIN EXPRESSION; SH SY5Y CELL; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION;

EID: 80054055671     PISSN: 16735374     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Leng Y, Marinova Z, Marcos A. Potent neuroprotective effects of novel structural derivatives of valproic acid: Potential roles of HDAC inhibition and HSP70 induction. Neurosci Lett. 2010;476(3): 127-132.
2. Brunello N. Mood stabilizers: protecting the mood protecting the brain. Affect Disord. 2004;79(1):15-20.
3. Aghdam SY, Barger SW. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: lessons from lithium. Curr Alzheimer Res. 2007;4(1):21-31.
4. Plant KE, Anderson E, Simecek N, et al. The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009;235(1): 124-134.
5. Bachmann RF, Wang Y, Yuan PX, et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol. 2009;12(6):805-822.
6. Ercegovac M, Jovic N, Simic T, et al. Byproducts of protein, lipid and DNA oxidative damage and antioxidant enzyme activities in seizure. Seizure. 2010;19(4):215-210.
7. Shao L, Young LT, Wang JF. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry. 2005;58(11):879-884.
8. King TD, Jope RS. Inhibition of glycogen synthase kinase-3 protects cells from intrinsic but not extrinsic oxidative stress. Neuroreport. 2005;16(6):597-601.
9. Lai JS, Zhao CN, Warsh JJ, et al. Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur J Pharmacol. 2006;539(1-2):18-26.
10. Cui J, Shao L, Young LT, et al. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience. 2007;144(4):1447-1453.
11. Cournoyer P, Desrosiers RR. Valproic acid enhances protein L-isoaspartyl methyltransferase expression by stimulating extracellular signal-regulated kinase signaling pathway. Neuropharmacology. 2009;56(5):839-848.
12. Flynn A, Proud CG. The role of eIF4 in cell proliferation. Cancer Surv. 1996;27(1):293-310.
13. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006;5(8): 671-688.
14. Carmel M, Alan P, Tariq ES, et al. The human eukaryotic initiation factor 4AI gene (EIF4A1) contains multiple regulatory elements that direct high-Level reporter gene expression in mammalian cell lines. Genomics. 1999;62(3):468-476.
15. Vo TK, Godard P, Saint-Hubert M, et al. Transcriptomic biomarkers of human ageing in peripheral blood mononuclear cell total RNA. Exp Gerontol. 2010;45(3):188-194.
16. Nusshold C, Kollroser M, Köfeler H. Hypochlorite modification of sphingomyelin generates chlorinated lipid species that induce apoptosis and proteome alterations in dopaminergic PC12 neurons in vitro. Free Radic Biol Med. 2010;48(12):1588-1600.
17. Matunis MJ, Michael WM, Dreyfuss G. Characterization and primary structure of the poly(C)-binding heterogeneous nuclear ribonucleoprotein complex K protein. Mol Cel Biol. 1992;12(1): 164-171.
18. Bomsztyk K, Denisenko O, Ostrowski J. hnRNP K: one protein multiple processes. Bioessays. 2004;26(6):629-638.
19. Ostareck LA, Ostareck DH, Hentze MW. Cytoplasmic regulatory functions of the KH-domain proteins hnRNPs K and E1/E2. Trends Biochem Sci. 1998;23(11):409-411.
20. Makeyev AV, Liebhaber SA. The poly(C)-binding proteins: a multiplicity of functions and a search for mechanisms. RNA. 2002; 8(3):265-278.
21. Michelotti EF, Michelotti GA, Aronsohn AI. Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol Cell Biol. 1996; 16(5):2350-2360.
22. Michael WM, Eder PS, Dreyfuss G. The K nuclear shuttling domain: a novel signal for nuclear import and nuclear export in the hnRNP K protein. EMBO. 1997;16(12):3587-3598.
23. Ostareck DH, Ostareck LA, Wilm M. mRNA silencing in erythroid differentiation: hnRNP K and hnRNP E1 regulate 15-lipoxygenase translation from the 3′ end. Cell. 1997;89(4):597-606.
24. Expert-Bezancon A, Le Caer JP, Marie J. Heterogeneous nuclear ribonucleoprotein (hnRNP) K is a component of an intronic splicing enhancer complex that activates the splicing of the alternative exon 6A from chicken beta-tropomyosin pre-mRNA. Biol Chem. 2002;277(19):16614-16623.
25. Denisenko O, Bomsztyk K. Yeast hnRNP K-like genes are involved in regulation of the telomeric position effect and telomere length. Mol Cell Biol. 2002;22(1):286-297.
26. Wei CC, Zhang SL, Chen YW. Heterogeneous nuclear ribonucleoprotein K modulates angiotensinogen gene expression in kidney cells. J Biol Chem. 2006;281(35):25344-25355.
27. Yano M, Okano J, Okano H. Involvement of Hu and heterogeneous nuclear ribonucleoprotein K in neuronal differentiation through p21 mRNA post-transcriptional regulation. Bio Chem. 2005;280(13):12690-12699.
28. Arendt T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-oraganization. Neuroscience. 2001;102(4):723-765.
29. Surendra S, Ambegaokar, Bidisha R. Neurodegenerative models in Drosophila: Polyglutamine disorders, Parkinson disease, and amyotrophic lateral sclerosis. Neurobiol Dis. 2010;40(1):29-39.
30. Dzwonek A, Mikula M, Ostrowski J. The diverse involvement of heterogeneous nuclear ribonucleoprotein K in mitochondrial response to insulin. FEBS Lett. 2006;580(7):1839-1845.
31. Gao FH, Wu YL, Zhao M. Protein Kinase C-δ mediates down-regulation of heterogeneous nuclear ribonucleoprotein K protein: involvement in apoptosis induction. Exp Cell Res. 2009; 315(19):3250-3258.
32. Revil T, Pelletier J, Toutant J. Heterogeneous Nuclear ribonucleoprotein k represses the production of pro-apoptotic bcl-x(s) splice isoform. J Bio Chem. 2009;284(32):21458-21467.
33. Nakamura M, Yamada M, Ohsawa T. Phosphoproteomic profiling of human SH-SY5Y neuroblastoma cells during response to 6-hydroxydopamine-induced oxidative stress. Biochim Biophys Acta. 2006;1763(9):977-989.
34. Satoh J, Nakanishi M, Koike F. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis. Neurobiol Dis. 2005;18(3):537-550.
35. Vantaggiato C, Redaelli F, Falcone S. A novel CLN8 mutation in late-infantile-onset neuronal ceroid lipofuscinosis (LINCL) reveals aspects of CLN8 neurobiological function. Hum Mut. 2009;30(7): 1104-1116.
36. 2+-ATPase acts as a proton pump. Biochem. 1984;95(4):995-1007.
37. Kadota M, Nishigaki R, Wang CC. Proteomic signatures and aberrations of mouse embryonic stem cells containing a single human chromosome 21 in neuronal differentiation: An in vitro model of down syndrome. Neuroscience. 2004;129(2):325-335.
38. Migliore L, Coppedè F. Environmental-induced oxidative stress in neurodegenerative disorders and aging. Mut Res. 2009;674(1-2): 73-84.
39. +-ATPase. Physiol Rev. 2004;84(4):1263-1314.
40. Chen YC, Yuo CY, Yang WK. Extracellular pH change modulates the exon 7 splicing in SMN2 mRNA. Mol Cel Neurosci. 2008;39(2): 268-272.
41. Pan TH, Li XQ, Xie WJ. Valproic acid-mediated Hsp70 induction and anti-apoptotic neuroprotection in SH-SY5Y cells. FEBS lett. 2005;579(30):6716-6720.
42. Zhang L, Chang M, Hu L. Proteomic changes of PC12 cells treated with proteasomal inhibitor PSI. Brain Res. 2007;1153(1): 196-203.
43. Jamesdaniel S, Salvi R, Coling D. Auditory proteomics: Methods, accomplishments and challenges. Brain Res. 2009;1277(1): 24-26.
44. Zhang W, Chait BT. ProFound: an expert system for protein identification using mass spectrometric peptide mapping information. Anal Chem. 2000;72(11):2482-2489.